Recombinant Human Anti-CD45 x Human Anti-Myosin Bispecific Antibody (scIgG) (SCIGG-H296)

Recombinant Anti-CD45 x Anti-Myosin Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD45 and anti-Myosin IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can recruit stem cells to infarcted myocardium. It is designed for the research of Myocardial infarction therapy.

Datasheet INQUIRY

Specifications

Targets

CD45 & Myosin

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Myocardial infarction

Targets

Target 1

CD45

Gene ID

5788

UniProt ID

P08575

Alternative Names

PTPRC; CD45; Cluster of differentiation 45; protein tyrosine phosphatase, receptor type C; LCA; LY5; B220; CD45; L-CA; T200; CD45R; GP180

Target 2

Myosin

Alternative Names

Myosin; ATP-dependent motor proteins

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD45 x Human Anti-Myosin Bispecific Antibody (scIgG) (SCIGG-H296). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD45 x Human Anti-Myosin Bispecific Antibody (scIgG) (CAT#: SCIGG-H296)

Specifications

Targets

Customer Reviews and Q&As